Business Wire

EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally

13.9.2023 11:00:00 EEST | Business Wire | Press release

Share

Boomi™, the intelligent connectivity and automation leader, today announced that leading UK-based technology distributor EXERTIS is expanding its use of Boomi’s category-leading, unified integration platform to improve partner and customer satisfaction on a global scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808691045/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally (Graphic: Business Wire)

EXERTIS works with 2,400 technology partners, including Apple, Samsung, Microsoft, and Dell Technologies, and serves more than 50,000 retailers and resellers in 20+ countries. As part of a full spectrum of services, EXERTIS supplies IT hardware and software to electronic retailers and hosts some clients’ ecommerce stores, managing their full, end-to-end customer journeys.

Prior to using Boomi, EXERTIS had grown through acquisition, where each of its operating entities possessed a mix of legacy and modern integration tools. As a result, manual custom coding; ageing, on-premises enterprise service bus (ESB) systems; and outdated electronic data interchange (EDI) tools and services were widespread and disconnected. This led to slow development and deployment of new integrations, high technical debt, and a declining pool of developers with specialised skills that stifled the scalability and flexibility EXERTIS needed.

With an acquisition strategy that benefitted from inter-company trade synergies, EXERTIS needed a future-proof solution. After evaluating various integration and EDI solutions, EXERTIS saw how Boomi could modernise its IT environment and support its growth and acquisition strategy through the platform’s low-code ease of use; speed of development; and multiple capabilities in a unified, multi-tenant, cloud-based solution.

Using its core integration, B2B/EDI management, and API management capabilities, the Boomi platform enables EXERTIS to connect into over 100 internal and third-party systems with 200 more systems in the pipeline, providing EXERTIS with the agility for further innovation.

“EXERTIS has its origins in venture capitalism and private equity, and a core part of our work centred around the integration of acquired entities,” said Tim Griffin, CEO, EXERTIS. “There are lots of solutions on the market, but I would put Boomi at the top, especially when you consider its multi-tenant architecture and cloud basis. Our developers became proficient in as little as three weeks, and we now have a shared development environment that promotes reuse of integrations across our business.”

In light of its early success, EXERTIS is expanding its use of Boomi to digitally transform its global environment for integration and EDI transactions, and improve partner and customer satisfaction on a global scale.

“We’re delighted to expand our engagement and support of EXERTIS as they continue to grow globally,” said Adrian Trickett, Vice President and General Manager, EMEA at Boomi. “By enabling frictionless transactions, EXERTIS has increased the percentage of orders from its partners and customers, and freed time for its people to pursue more value-adding work.”

Learn more about the EXERTIS use case with Boomi here.

Additional Resources

About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organisations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.

© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye